Aucta Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aucta Pharmaceuticals, Inc. - overview
Established
2012
Location
Shanghai, -, China
Primary Industry
Pharmaceuticals
About
Based in Shanghai, China and founded in 2012, Aucta Pharmaceuticals, Inc. is a developer focusing on the research and development of generic drugs and new dosage forms. The company's founder Dr. Li has 20 years of pharmaceutical industry experience, he is responsible for the overall strategy, direction, and growth of the business.
He once served as manager in Novartis Pharmaceuticals and Eon Labs. The company is creating new therapeutics, including new dosage forms, new dosing regimens and new indications. The company is developing products in CNS, in particular, epilepsy, Dermatology and Pediatrics. There are 3 programs undergoing Ph2/Ph3 clinical trials, one of which is an orphan drug product, two of which are innovative in nature.
The company also has more than 10 pipeline products at various stages of development.
Current Investors
Fang Fund Partners, Grand Yangtze Capital, Co-Win Ventures
Primary Industry
Pharmaceuticals
Sub Industries
Specialty Pharmaceuticals
Website
www.auctapharma.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.